Cardinal Health price target raised to $74 from $66 at Mizuho

Mizuho analyst Ann Hynes raised the firm’s price target on Cardinal Health to $74 from $66 and keeps a Neutral rating on the shares post the Q3 results. The recovery in core business volumes remains a tailwind for the drug distributors, Hynes tells investors in a research note.